<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Aug. 2, 2019 (HealthDay News) — Plasma \u03b2-amyloid (A\u03b2)42\/A\u03b240 corresponds with amyloid positron emission tomography (PET) status, according to a study published online Aug. 1 in Neurology<\/i>.<\/p>\n
Suzanne E. Schindler, M.D., Ph.D., from the Washington University School of Medicine in St. Louis, and colleagues measured A\u03b242\/A\u03b240 in plasma and cerebrospinal fluid (CSF) samples obtained from 158 mostly cognitively normal individuals within 18 months of an amyloid PET scan.<\/p>\n
The researchers identified high correspondence for plasma A\u03b242\/A\u03b240 with amyloid PET status (receiver operating characteristic area under the curve [AUC], 0.88) and CSF p-tau181\/A\u03b242 (AUC, 0.85). There was a very high correspondence for the combination of plasma A\u03b242\/A\u03b240, age, and APOE<\/i> \u03b54 status with amyloid PET (AUC, 0.94). Compared with individuals with a negative plasma A\u03b242\/A\u03b240, those with a negative amyloid PET scan at baseline and a positive plasma A\u03b242\/A\u03b240 had a 15-fold higher risk for conversion to amyloid PET-positive.<\/p>\n
“More comprehensive studies are currently underway to further validate this assay in multiple large international cohorts,” the authors write. “If further validated, this assay will accelerate progress towards an effective therapy for Alzheimer disease by decreasing the time, cost, and risk of drug trials, and one day enable a blood test in the clinic to identify patients who could benefit from disease-modifying treatment.”<\/p>\n
Several authors disclosed financial ties to biopharmaceutical companies, including Eli Lilly\/Avid Radiopharmaceuticals, which provided partial financial support. Two authors have submitted a provisional patent application.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n